Strong Q4 Revenue and EPS
Q4 sales of $932 million, up 7% reported and 6% constant currency; adjusted EPS $4.53 (GAAP EPS $3.77). Recurring revenue grew 9% in the quarter, supporting margin strength.
Full-Year Growth and Profitability
Full-year revenue grew 7% (reported and constant currency). Adjusted EPS grew 11% to $13.13 (GAAP EPS $10.76). Full-year gross margin 59.3% and adjusted operating margin 30.5%. Full-year free cash flow $677 million.
Recurring Revenue and LC‑MS Momentum
Full-year recurring revenue grew 8% (service +7%, chemistry +12%). Instrument revenue grew 5% for the year with LC‑MS delivering high single-digit growth or better every quarter.
Commercial KPI Improvements & E‑commerce
Service plan attachment rose to 54% (≈ +400 basis points YoY). Instrument replacement tracking at ~2.5% CAGR vs 2019 (≈ +100 bps since cycle start). E‑commerce penetration reached ~45% of consumables revenue. Contract organizations represent 27% of pharma sales (up from 15% five years ago).
Product Innovation Driving Growth
Multiple new-product successes: Alliance iS HPLC sales more than doubled; Xevo TQ Absolute platforms grew >30%; MaxPeak Premier chemistry grew >35%; chemistry/bioseparations expanded with double-digit growth in 2025 (SEC columns, slalom chromatography, affinity separations).
Acquisition Closed with Clear Synergy Targets and Solid Combined Guidance
Closed BD Biosciences & Diagnostic Solutions acquisition. Acquired business expected to contribute ~$3.0 billion revenue in 2026. Combined 2026 reported revenue guidance ~$6.405B–$6.455B (blended ~5.3% YoY at midpoint). Expect ~$55M of cost synergies and ~$50M of revenue synergies in 2026 (with ~$25M adjusted EBIT from revenue synergies). Combined adjusted operating margin ~28.1% and adjusted EPS guidance $14.30–$14.50 (8.9%–10.4% growth, includes ~$0.10 accretion).
Healthy Cash Generation and Defined Deleveraging Path
Q4 free cash flow $125M after $39M capex; full-year free cash flow $677M after $113M capex. Pro forma net debt expected ~$4.6–$4.7B (≈2.4x net debt/EBITDA) with plan to reduce to below 2x within ~18 months.